Which has more human data?

Going by the research status on each profile (CJC-1295 (with DAC): Phase 1 / early human; CJC-1295 (no DAC): Preclinical (animal)), CJC-1295 (with DAC) is furthest along in human testing. Research status describes the stage of the published evidence, not whether a compound works or is safe.

What are the half-lives?

CJC-1295 (with DAC): 6-8 days. CJC-1295 (no DAC): No published PK data found. Figures are as reported in the cited studies, with the species where stated.

Are they FDA-approved?

CJC-1295 (with DAC): research status “Phase 1 / early human”. Not FDA-approved. Not among the peptides named in the 2026 PCAC actions. CJC-1295 (no DAC): research status “Preclinical (animal)”. See the FDA peptide regulatory tracker for sourced compounding status.

How are they administered in the research?

CJC-1295 (with DAC): Subcutaneous injection. CJC-1295 (no DAC): Subcutaneous injection. This describes the published studies and is not a recommendation for human use.

CJC-1295 (with DAC) vs CJC-1295 (no DAC): Research Comparison

Built from the CJC-1295 (with DAC), CJC-1295 (no DAC) research profiles · Profiles last updated October 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team

TL;DR

This page compares CJC-1295 (with DAC) and CJC-1295 (no DAC) using only their research-profile data. CJC-1295 (with DAC) (research stage: Phase 1 / early human; half-life: 6-8 days). It is a long-acting version of the hormone that tells the pituitary to release growth hormone, so its effect lasts for days. CJC-1295 (no DAC) (research stage: Preclinical (animal); half-life: Not established in published research). It is expected to prompt the pituitary gland to release growth hormone, based on similar compounds; it has not been studied directly. Educational summary, not medical advice.

Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies

Educational summary. Everything below is taken from each compound's research profile and describes what was reported in the cited studies — not a promise of results, a dose recommendation, or an endorsement for human use. Not medical advice. Full disclaimer.

Side-by-side comparison

	CJC-1295 (with DAC)	CJC-1295 (no DAC)
Category	Growth Hormone	Growth Hormone
Research status	Phase 1 / early human	Preclinical (animal)
Regulatory note (as of Sept 2026)	Not FDA-approved. Not among the peptides named in the 2026 PCAC actions. Regulatory tracker →	— Regulatory tracker →
Half-life	6-8 days	No published PK data found
Administration route	Subcutaneous injection	Subcutaneous injection
Dosing used in published research (not a recommendation)	Healthy adults aged 21-61: single s.c. ascending doses, then 2-3 weekly or biweekly s.c. doses. Best tolerated at 30 or 60 µg/kg (Teichman 2006). That is about 2-4 mg per dose for a 70 kg adult, given once, weekly or every 2 weeks, over 28-49 days.	No published studies of Mod GRF(1-29)/CJC-1295 no DAC found. CJC-1295 with DAC: 30 or 60 µg/kg s.c. single/weekly doses in healthy adults. Sermorelin: 1 µg/kg i.v. as a diagnostic GH stimulation test in children.
Community-reported protocol (not from clinical studies)	Community-reported1–2 mg per week, subcutaneous injection	Community-reported100–200 mcg, subcutaneous injection
How it works (as summarized from the cited research)	In plain terms: It is a long-acting version of the hormone that tells the pituitary to release growth hormone, so its effect lasts for days. GHRH analogue with a drug affinity complex (DAC) modification designed to bind albumin and prolong its action. In two placebo-controlled trials in healthy adults, single and repeated subcutaneous doses produced prolonged increases in GH and IGF-I (Teichman 2006).	In plain terms: It is expected to prompt the pituitary gland to release growth hormone, based on similar compounds; it has not been studied directly. Proposed mechanism, inferred from related GHRH analogues (no published studies of this compound were found): a GHRH-receptor agonist expected to stimulate pituitary GH release. The related GHRH analogue sermorelin (GRF 1-29) stimulates GH secretion from the anterior pituitary (Prakash 1999).
Effects reported in research (study subjects as stated)	ClinicalRaised GH 2-10-fold for ≥6 days and IGF-I 1.5-3-fold for 9-11 days in healthy adults (Teichman 2006)	Lab / animalIn animal studies: enhanced GH release Body composition, recovery, sleep and anti-aging effects are hypothesized based on GHRH pharmacology; no published studies of this compound
Potential side effects	ClinicalNo serious adverse reactions in the Teichman 2006 trials; tolerability was best at 30-60 µg/kg Long-term human safety data are lacking	No published human safety data for the no-DAC form ClinicalFor CJC-1295 with DAC: injection-site reactions and no serious adverse events in 28-49 day trials (PMID 16352683)
Profile description	CJC-1295 with Drug Affinity Complex that extends half-life dramatically, providing sustained GH elevation over days rather than hours.	Modified Growth Hormone Releasing Factor (1-29), proposed to provide more stable GH release when combined with GHRPs (no primary study found). Also known as Mod GRF 1-29.
References cited on the profile	1	2

Key differences in the published research

Research status: CJC-1295 (with DAC) — Phase 1 / early human; CJC-1295 (no DAC) — Preclinical (animal).
Category: the same on every profile (Growth Hormone).
Reported half-life: CJC-1295 (with DAC) — 6-8 days; CJC-1295 (no DAC) — No published PK data found.
Administration route in the literature: the same on every profile (Subcutaneous injection).
Evidence cited: CJC-1295 (with DAC)’s profile lists 1 reference; CJC-1295 (no DAC)’s profile lists 2 references.

Regulatory status

CJC-1295 (with DAC): Not FDA-approved. Not among the peptides named in the 2026 PCAC actions. Details →
CJC-1295 (no DAC): No regulatory note on its profile. Details →

For the sourced, dated status of every peptide in FDA's 2026 compounding actions, see the FDA peptide regulatory tracker.

Frequently Asked Questions

Which has more human data?: Going by the research status on each profile (CJC-1295 (with DAC): Phase 1 / early human; CJC-1295 (no DAC): Preclinical (animal)), CJC-1295 (with DAC) is furthest along in human testing. Research status describes the stage of the published evidence, not whether a compound works or is safe.
What are the half-lives?: CJC-1295 (with DAC): 6-8 days. CJC-1295 (no DAC): No published PK data found. Figures are as reported in the cited studies, with the species where stated.
Are they FDA-approved?: CJC-1295 (with DAC): research status “Phase 1 / early human”. Not FDA-approved. Not among the peptides named in the 2026 PCAC actions. CJC-1295 (no DAC): research status “Preclinical (animal)”. See the FDA peptide regulatory tracker for sourced compounding status.
How are they administered in the research?: CJC-1295 (with DAC): Subcutaneous injection. CJC-1295 (no DAC): Subcutaneous injection. This describes the published studies and is not a recommendation for human use.
How do their proposed mechanisms differ?: CJC-1295 (with DAC): In plain terms: It is a long-acting version of the hormone that tells the pituitary to release growth hormone, so its effect lasts for days. GHRH analogue with a drug affinity complex (DAC) modification designed to bind albumin and prolong its action. In two placebo-controlled trials in healthy adults, single and repeated subcutaneous doses produced prolonged increases in GH and IGF-I (Teichman 2006). CJC-1295 (no DAC): In plain terms: It is expected to prompt the pituitary gland to release growth hormone, based on similar compounds; it has not been studied directly. Proposed mechanism, inferred from related GHRH analogues (no published studies of this compound were found): a GHRH-receptor agonist expected to stimulate pituitary GH release. The related GHRH analogue sermorelin (GRF 1-29) stimulates GH secretion from the anterior pituitary (Prakash 1999). These are mechanisms proposed in the cited research, at the research stage listed for each compound.

References

CJC-1295 (with DAC)

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. The Journal of clinical endocrinology and metabolism. 2006. PMID: 16352683.
Study type: Two randomized placebo-controlled ascending-dose trials, healthy adults.
DOI: 10.1210/jc.2005-1536 · PubMed

CJC-1295 (no DAC)

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash A, Goa KL. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 1999. PMID: 18031173.
Study type: Drug review (GRF 1-29 analog).
DOI: 10.2165/00063030-199912020-00007 · PubMed

Read the full profiles

From Our Affiliated Clinic

Curious about supervised growth hormone protocols?

1836 Wellness — operated by the same company as The Peptide Dispatch — offers physician-supervised protocols, 76-marker blood panels, and bio-age scoring.

Visit 1836 Wellness →

Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.

Educational content — not medical advice. Effects described are drawn from cited research in study subjects.

← Compare Peptides Peptide Database Regulatory Tracker Home